Tislelizumab (BGB-A317)

DRUG3 trials

Sponsors

BeiGene, Oncomatryx Biopharma S.L., Beijing Friendship Hospital

Conditions

Advanced Solid TumorMCRCMSI-H/dMMR Solid Tumors

Phase 1

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

RecruitingNCT05547321

Oncomatryx Biopharma S.L.Advanced Solid Tumor

Start: 2022-10-20End: 2027-12-31Target: 150Updated: 2025-11-25

Phase 2

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

RecruitingNCT03736889

BeiGeneMSI-H/dMMR Solid Tumors

Start: 2018-09-19End: 2027-09-30Target: 200Updated: 2025-12-17

Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer

RecruitingNCT06829355

Beijing Friendship HospitalMCRC

Start: 2025-02-11End: 2027-12-31Target: 52Updated: 2025-02-17

Related Papers

First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.

Journal of Clinical Oncology2025-05-284 citations

Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.

Journal of Clinical Oncology2024-06-013 citations

Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

Journal of Clinical Oncology2022-06-012 citations

Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

Journal of Clinical Oncology2022-01-195 citations

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.

Journal of Clinical Oncology2021-05-2014 citations